glp-1 agonists and pancreatitis Adverse effects of GLP-1 class

Expert Opin Drug Metab Toxicol

Aigner, T., Haag, J., Martin, J

10,11 Regarding IOP-lowering mechanisms, GLP-1RAs have been shown to inhibit sodium-potassium ATPase in the choroid plexus, decreasing cerebrospinal fluid secretion and lowering intracranial pressure

The GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist Market is undergoing a paradigm shift, transforming from a niche therapeutic class primarily used in type 2 diabetes management to a multi-billion-dollar market at the heart of the global obesity epidemic

Sci Rep 2024

New risks include increased aspiration risk during anesthesia due to delayed gastric emptying and challenges with bowel preparation for colonoscopies [50] [51] [52]